Tarceva and Metastasis - a phase IV clinical study of FDA data

Summary:

Metastasis is reported as a side effect among people who take Tarceva (erlotinib hydrochloride), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Avastin, and have Malignant respiratory tract neoplasm.

The phase IV clinical study analyzes which people have Metastasis when taking Tarceva. It is created by eHealthMe based on reports of 30,795 people who have side effects when taking Tarceva from the FDA, and is updated regularly.

What is Tarceva?

Tarceva has active ingredients of erlotinib hydrochloride. It is often used in lung cancer. eHealthMe is studying from 31,036 Tarceva users. Check the latest studies of Tarceva.

What is Metastasis?

Metastasis (spreadable cancer to other organ from origin) is found to be associated with 532 drugs and 842 conditions by eHealthMe. Check the latest studies of Metastasis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Jul, 31, 2026

30,795 people reported to have side effects when taking Tarceva.
Among them, 98 people (0.32%) have Metastasis.

Among these 98 people:

How long have people been on Tarceva when they have Metastasis? *

What is the gender of people who have Metastasis when taking Tarceva? *

female: 54.17 %
male: 45.83 %

What is the age of people who have Metastasis when taking Tarceva? *

What are other drugs people take besides Tarceva? *

What are other side effects people have besides Metastasis? *

Death: 55 people, 56.12%
Pain: 13 people, 13.27%
Rashes (redness): 10 people, 10.20%
Weakness: 9 people, 9.18%
Diarrhea: 8 people, 8.16%
Malaise (a feeling of general discomfort or uneasiness): 7 people, 7.14%
Dyspnea (difficult or laboured breathing): 7 people, 7.14%
Pleural Effusion (water on the lungs): 7 people, 7.14%
Cough: 6 people, 6.12%
Disease Progression: 6 people, 6.12%

What are the existing conditions these people have? *

Malignant Respiratory Tract Neoplasm (cancer tumour of respiratory tract): 42 people, 42.86%
Lung Neoplasm Malignant (cancer tumour of lung): 16 people, 16.33%
Pancreatic Carcinoma (pancreatic cancer): 11 people, 11.22%
Renal Cell Carcinoma (a kidney cancer): 10 people, 10.20%
Malignant Urinary Tract Neoplasm (cancer tumour of urinary tract organs): 5 people, 5.10%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 3 people, 3.06%
Lung Cancer Metastatic (lung cancer spreads to other parts): 2 people, 2.04%
Renal Cell Carcinoma Stage Unspecified (kidney cancer in unknown stage): 1 person, 1.02%
Lung Carcinoma Cell Type Unspecified Stage 0 (the lung cancer has not spread beyond the inner lining of the lung): 1 person, 1.02%
Bone Neoplasm Malignant (cancer of bone): 1 person, 1.02%

* Approximation only. Some reports may have incomplete information.

Do you take Tarceva and have Metastasis?

- Check whether Metastasis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tarceva:

Tarceva (31,036 reports)

Metastasis treatments and more:

Metastasis (11,222 reports)

Browse all side effects of Tarceva:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Metastasis:

Metastasis (532 drugs)

Browse all the conditions that are associated with Metastasis:

Metastasis (842 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on erlotinib hydrochloride (the active ingredients of Tarceva) and Tarceva (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.